NeuroPace Inc. (NPCE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
NeuroPace Q2 Earnings Call Highlights
NeuroPace NASDAQ: NPCE reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook. The company also said it is pursuing additional discussions with the U.S. Food and Drug Administration regarding its application to expand the RNS System's indication into idiopathic generalized epilepsy, or IGE.
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.
NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript
NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
NeuroPace NASDAQ: NPCE said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant idiopathic generalized epilepsy, or IGE, was not approvable in its current form.
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
